Loading
Lymphoblastic Leukemia / Immunotherapy, Adoptive / Receptors, Chimeric Antigen · Journal article
Human Vaccines & Immunotherapeutics · July 20, 2026
The material analysed did not support any firm read.
This bibliometric analysis maps the global research landscape of CAR-T therapy for acute lymphoblastic leukemia across 844 publications, identifying research trends and key contributors. The analysis reveals evolution from basic science through clinical translation to current focus on long-term outcomes and risk assessment, but provides no clinical efficacy or safety data.
Bibliometric analysis. 844 articles on CAR-T cell therapy for acute lymphoblastic leukemia published in 253 journals by 6,459 authors from 44 countries. n = 844. 44 countries, dominated by USA and China.
844 articles from 253 journals by 6,459 authors across 44 countries analyzed, showing an annual growth rate of 40.08% USA dominated with 372 articles and 38,065 citations, followed by China with 275 articles and 5,636 citations University of Pennsylvania was most productive with 353 articles
No clinical outcomes, efficacy, or safety data reported Research evolved from basic science (2010-2013) to clinical translation (2014-2016), toxicity management (2017-2019), and long-term outcomes (2020-2024)
This analysis provides no actionable clinical evidence but identifies research priorities including biomarker development, next-generation CAR designs, and combination strategies to address persistence, toxicity, and resistance. Clinicians seeking evidence on CAR-T efficacy or safety should consult primary clinical studies.
Bibliometric analysis of 844 publications provides research landscape mapping but no clinical efficacy or safety data.
As stated by the source record.
Quoted from the source exactly as published.
This analysis provides no actionable clinical evidence but identifies research priorities including biomarker development, next-generation CAR designs, and combination strategies to address persistence, toxicity, and resistance. Clinicians seeking evidence on CAR-T efficacy or safety should consult primary clinical studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This study aims to analyze the global research patterns and emerging trends in CAR-T cell therapy for ALL through a bibliometric analysis. Publications were retrieved from the Web of Science Core Collection database. The bibliometric analysis utilized VOSviewer, CiteSpace, and the R package "bibliometrix" to visualize collaborations, keyword co-occurrences, and emerging research trends. A total of 844 articles from 253 journals by 6,459 authors across 44 countries were analyzed, showing an annual growth rate of 40.08%. The USA (372 articles, 38,065 citations) and China (275 articles, 5,636 citations) dominated research output. The University of Pennsylvania (353 articles), Memorial Sloan Kettering Cancer Center (170), and Children's Hospital of Philadelphia (131) were the most productive institutions, while Blood (41 articles) published the most articles. Stephan A. Grupp (38 articles, H-index = 30), Carl H. June (26 articles, H-index = 24), and Shannon L. Maude (25 articles, H-index = 20) were the most influential authors. Keyword analysis revealed five research clusters, including basic mechanisms, CAR design, population treatment integration, clinical outcomes, and toxicity management. Burst keyword analysis showed the evolution from basic science (2010-2013) to clinical translation (2014-2016), toxicity management (2017-2019), and recently to long-term outcomes and risk assessment (2020-2024), with "term follow-up" and "risk" as the only keywords with active bursts in 2024. This bibliometric analysis reveals that research on CAR-T therapy for ALL has progressed from foundational concepts to clinical implementation and now focuses on optimizing long-term outcomes and patient selection. Future research should prioritize biomarker development, next-generation CAR designs, and combination strategies to overcome persistence, toxicity, and resistance limitations in ALL treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.